Johnson and Johnson 2006 Annual Report Download - page 31

Download and view the complete annual report

Please find page 31 of the 2006 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 84

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84

Cordis Corporation Portfolio Benefits From
Acquisitions, Agreements and R&D
In 2006 two strategic acquisitions and three
licensing transactions further strengthened
Cordis’ global leadership position in
interventional cardiology and other strategic
business areas. In all, these transactions
contributed 12 new product introductions
from this franchise last year.
The acquisition of Ensure Medical, Inc.,
a privately held company in Sunnyvale, Calif., that develops
devices for post-catheterization closure of the femoral artery,
further expands Cordis’ presence in California. In 2006,
it launched Accelerated Medical Ventures, a state-of-the-
art advanced research and development facility in the San
Francisco Bay area.
The Johnson & Johnson acquisition of
Conor Medsystems, Inc., completed in February 2007, is
expected to complement the existing drug-eluting stent
business with a unique controlled drug-delivery technology.
The acquisition provides
a unique drug-delivery
technology to be explored
across a range of therapeutic
categories, and it
immediately contributes to
the development of next-
generation technologies
aimed at advancing the
standard of care in the
treatment of cardiac and
vascular disease.
On the distribution front,
Cordis signed a distribution
agreement with Brivant
Ltd. for three interventional guidewire products that will be
marketed under an umbrella brand known as REGATTA™. Cordis
also signed an agreement with ClearStream Technologies
Group, PLC for distribution rights to the CRESCENDO™ PTCA
(Percutaneous Transluminal Coronary Angioplasty)
Balloon Dilation Catheter in all countries except the U.S.,
Japan and Canada.
In addition, BioSense Webster, Inc., part of the Cordis
franchise, secured exclusive worldwide rights to distribute
Siemens Medical Solutions’ state-of-the-art cardiac catheters,
ACUSON AcuNav™ ultrasound catheters, to electrophysiologists.
TRANSFORMING DIABETES CARE
From Measurement
to Management
Y E A R I N R E V I E W
2006 YEAR IN REVIE W:
Medical Devices & Diagnostics
• 59 New Products Extend Global Leadership in Medical Technology
• Six Major Acquisitions Expand Key Business Portfolios
The Cordis portfolio
continued to grow in 2006 with
the addition of a dozen new
products, including:
CYPHER® SELECT™ PLUS, the first third-
generation drug-eluting stent launched
in major global markets (except the U.S.
and Japan)
CARTO® RMT V8 and Niobe Integrated
Electroanatomical Navigation System
PRECISE® Nitinol Stent
ANGIOGUARD® Emboli Capture
Guidewire
LifeScan, Inc. is more focused
than ever on moving from
simple blood glucose
measurement to diabetes
management in order to
deliver improved patient health
outcomes. It’s doing that by
offering patients and providers
tools that give better insight
into disease management, such
as the OneTouch® Ultra®2
Blood Glucose Monitor, which
helps patients link the effects of
food to blood glucose results.
LifeScan, Inc. also offers
products that provide greater
access to blood glucose
monitoring in both developed
and developing markets. The
new OneTouch® UltraMini™
Blood Glucose Monitor
(also marketed as OneTouch®
UltraEasy™ in some countries)
offers just the basics of testing
in a small, affordable, simple-
to-use monitor to encourage
appropriate testing and greater
glucose control.
Similarly, the OneTouch®
Horizon® Blood Glucose
Monitor was specifically
designed to provide greater
access to testing in developing
markets such as India, where
currently only 7 percent of the
more than 35 million people
with diabetes are monitoring
their blood glucose. Patients
in these markets require the
simple, discrete and affordable
testing offered by the
OneTouch® Horizon® Monitor.
The 2006 acquisition of
Animas Corporation, a
company specializing in
insulin delivery systems, was
a key development for the
Johnson & Johnson diabetes
franchise. LifeScan and Animas
are working together to provide
a superior range of integrated
solutions for insulin delivery
and blood glucose monitoring
to simplify diabetes control
for patients using insulin and
their health care professionals.
29